OKYO - OKYO Pharma Ltd ADR

OKYO - OKYO Pharma Ltd ADR

https://okyopharma.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma - OKYO Pharma ( NASDAQ:OKYO )

Benzinga • 2 years, 4 months ago • score: 0.46

Dr. Gary S. Jacob, CEO of OKYO Pharma OKYO, was recently a guest on Benzinga's All Access. OKYO Pharma is a biotechnology company focused on the treatment of ocular diseases. OKYO is currently developing OK-101 to treat dry eye disease, which is a currently underserved and untreated condition ...

OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform - OKYO Pharma ( NASDAQ:OKYO )

Benzinga • 2 years, 4 months ago • score: 0.33

LONDON and NEW YORK, May 11, 2023 ( GLOBE NEWSWIRE ) -- OKYO Pharma Limited ( OKYOOKYO, an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that ...

OKYO Pharma Reports First Patient Visit For Phase 2 Trial Of OK-101, To Fulfill One Of The Two Phase 3 Studies Required For FDA Approval If Successful - OKYO Pharma ( NASDAQ:OKYO )

Benzinga • 2 years, 4 months ago • score: 0.50

OKYO Pharma Limited OKYO OKYO announced that the first patient has been screened for its phase 2, multicenter, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease ( DED ) .

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery ( ASCRS 2023 ) in San Diego, CA, May 5-8, 2023

GlobeNewswire • 2 years, 4 months ago • score: 0.09

LONDON and NEW YORK, May 03, 2023 ( GLOBE NEWSWIRE ) -- OKYO Pharma Limited ( LSE: OKYO. NASDAQ: OKYO or the "Company" ) , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease ( DED ) to address the significant unmet need in this ...

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

GlobeNewswire • 2 years, 4 months ago • score: 0.37

LONDON and NEW YORK, May 02, 2023 ( GLOBE NEWSWIRE ) -- OKYO Pharma Limited ( LSE: OKYO. NASDAQ: OKYO ) , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, is pleased ...

OKYO Pharma Activates First Clinical Trial Site For Phase 2 Study Of OK-101 To Treat Dry Eye Disease - OKYO Pharma ( NASDAQ:OKYO )

Benzinga • 2 years, 4 months ago • score: 0.12

OKYO Pharma Limited OKYO OKYO announced the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye pain in the UK. The company is headquartered in London, the United Kingdom.

52W High

$3.35

52W Low

$0.90

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-4.23

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-4.29

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

14.11

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

33.31%

Institutions (25–75% balanced)

7.37%

Shares Outstanding

37,610,700

Float

25,081,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-4,837,653

EPS (TTM)

-0.12

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-29.69%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.1569

Previous

-0.1575

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025